J Breast Cancer.  2006 Mar;9(1):25-30. 10.4048/jbc.2006.9.1.25.

The Proteomics Approaches to Find Bio-Markers in Serum of Locally Advanced Breast Cancer Patients

• Ryu JW
• Kim HJ
• Kim DH
• Song IH
• Park JY
• Hwang CH
• Kim SY

• KMID: 1976164
• DOI: http://doi.org/10.4048/jbc.2006.9.1.25

Abstract

PURPOSE
Breast cancer continues to be a major cause of death, despite the advances in the study of many prognostic factors. Although many prognostic factors have been studied, none reliably predict the response to treatment. This uncertainty in the prognostic factors could be overcome by defining the changes, occurring in patients at either the gene or protein level. Herein, attempts were made to examine the protein repertoire of patients using Proteomics.
MATERIALS AND METHODS
Using conventional Proteomics, the high resolution 2-D electrophoresis followed by computational image analysis(Melanie program) and protein identification with mass spectrometry (MALDI-TOF), the serum of locally advanced breast cancer patients (stage III) was analyzed, and attempts were made to define the differences between recurred (or metastasis) patients ,and disease free patients of more than 4-years duration after surgery.
RESULTS
In the 2-D electrophoresis of serum, about 1,000 spots were gained in each gel, with the up and down expressed protein spots compared to the normal control protein map. Six of seven patients had Cytokeratin 9 in their peripheral blood. In the serum of recurred patients (one of two), no Haptoglobin-related proteins were detected. All five un-recurred patients had normal or elevated levl of serum Haptoglobin-related proteins.
CONCLUSIONS
The reduction of Haptoglobin-related proteins indicated the humoral immuno-depression in recurred patients. These findings may suggest the continuation of proper humoral immunity was important in the prevention of cancer recurrences or metastasis after surgery, especially in locally advanced breast cancer patients, which may suggests the value of immunotherapy in breast cancer patients to obtain good results.

Keyword

breast cancer; serum; proteome analysis; proteomics

MeSH Terms

Breast Neoplasms*
Breast*
Cause of Death
Electrophoresis
Humans
Immunity, Humoral
Immunotherapy
Keratin-9
Mass Spectrometry
Neoplasm Metastasis
Proteomics*
Recurrence
Uncertainty
Keratin-9

Reference

1. Hunt KK, Ames FC, Singletary SE, Buzdar AU, Hortobagyi GN. Locally advanced noninflammatory breast cancer. The Surgical Clinics of North America. 1996. 76:393–410.

2. Hortobagyi GN. Comprehensive management of locally advanced breast cancer. Cancer. 1990. 66:1387–1391.

3. Schwartz GF, Birchansky CA, Komarnicky LT, Mansfield CM, Cantor RI, Biermann WA, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer. 1994. 73:362–369.

4. The Korean Breast Cancer Society. Nationwide Korean breast cancer data of 2002. J Korean Breast Cancer Soc. 2004. 7:72–83.

5. McCready DR, Hortobagyi GN, Kau SW, Smith TL, Buzdar AU, Balch C. The prognostic significance of lymph node metastasis after preoperative chemotherapy for locally advanced breast cancer. Arch Surg. 1989. 124:21–25.

6. Somiari RI, Somiari S, Russel S, Shriver CD. Proteomics of breast carcinoma. J Chromatography B. 2005. 815:215–225.

7. Li J, Zhang Z, Rosenweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem. 2002. 48:1296–1304.

8. Chan DW, Sell S. Burtis CA, Ashwood ER, editors. Tumor markers. Tietz fundamental of clinical chemistry. 2001. 5th ed. Philadelphia: WB Saunders;390–413.

9. Bisca A, D'Ambrosia C, Scaloni A, Puglisi F, Aprile G, Piga A, et al. Proteomic evaluation of core biopsy specimens from breast lesions. Cancer Lett. 2004. 204:79–86.

10. Somiari RI, Sullivan A, Russell S, Somiari S, Hu H, Jordan R, et al. High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics. 2003. 3:1863–1873.

11. Wulfkuhle JD, Sgroi DC, Krutzch H, McLean K, McGarvey K, Knowlton M, et al. Proteomics of human breast ductal carcinoma in situ. Cancer Research. 2002. 62:740–749.

12. Hathout Y, Gehrmann ML, Chertov A, Fenselau C. Proteomic phenotyping: metastatic and invasive breast cancer. Cancer Lett. 2004. 210:245–253.

13. Goncalves A, Esterni B, Bertucci F, Chabannon C, Cabizolles M, Bardou VJ, et al. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene. 2006. 25:981–989.